Damora Therapeutics Stock (NASDAQ:DMRA)
Previous Close
$26.01
52W Range
$2.45 - $38.33
50D Avg
$23.81
200D Avg
$21.13
Market Cap
$1.73B
Avg Vol (3M)
$500.46K
Beta
1.48
Div Yield
-
DMRA Company Profile
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.